Genmab
GMAB
180 hedge funds and large institutions have $1.15B invested in Genmab in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 57 increasing their positions, 82 reducing their positions, and 37 closing their positions.
13,678% more call options, than puts
Call options by funds: $4.41M | Put options by funds: $32K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
5.39% less ownership
Funds ownership: 59.46% → 54.07% (-5.4%)
11% less capital invested
Capital invested by funds: $1.3B → $1.15B (-$146M)
12% less funds holding
Funds holding: 204 → 180 (-24)
30% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 82
54% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 37
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$24.1M |
| 2 |
Morgan Stanley
New York
|
+$20.2M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$13.8M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$5.91M |
| 5 |
F
Folketrygdfondet
Oslo Norway,
Norway
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$40M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$31.8M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$24.8M |
| 4 |
Goldman Sachs
New York
|
-$14.7M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$14.1M |
GMAB Hedge Fund Activity: Q2 2022 in Review
180 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q2 2022, worth a combined $1.15B — down 11% from $1.3B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of GMAB and 17 opened new positions — a net loss of 20 holders — while 82 trimmed existing stakes and 57 added.
The largest buyer was Capital International Investors, adding an estimated $24.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $40M.
- 180 institutional investors held Genmab (GMAB) as of Q2 2022, down from 204 in Q1 2022.
- Funds reported $1.15B of Genmab stock for Q2 2022, down 11% quarter-over-quarter.
- 17 funds opened new Genmab positions in Q2 2022 and 37 closed out, a net change of -20 holders.
- The largest Genmab buyer in Q2 2022 was Capital International Investors, an estimated $24.1M added.
- The largest Genmab seller in Q2 2022 was T. Rowe Price Associates, an estimated $40M sold.
Based on aggregated 13F filings for Q2 2022.